As you may know, the annual ASCO (American Association of Clinical Oncology) meeting will be in Chicago from June 2-6. This is the world's biggest cancer meeting; literally tens of thousands of doctors,scientists, industry people, advocates, journalists, etc. attend. There is always breaking news, and occasionally there is game-changing news.
This is an early reminder to read or listen to any news reports with a somewhat skeptical ear. Hopefully there will be encouraging reports, but there is not going to be magic. A good way to follow along is through ASCO's Cancer Net, Here is information about how to do that a few early announcements:
The 2017 ASCO Annual Meeting Is just a few weeks away! From June 2nd to June 6th, more than 38,000 cancer specialists from around the world will gather in Chicago to present and discuss the latest research in treatment and patient care.
Throughout the meeting, ASCO's patient education website, Cancer.Net, will keep you updated on the scientific highlights with this special series of Inside Cancer.Net newsletters and with daily posts on the Cancer.Net Blog, discussing what this news means for patients, caregivers, and families. Please share these newsletters and blog posts with others who want to know more about the latest cancer research news.
Eating tree nuts could help reduce colon cancer recurrence. Another study of people diagnosed with stage III colon cancer who ate 2 or more ounces of tree nuts (such as almonds, walnuts, hazelnuts, cashews, and pecans) a week had a lower chance of the cancer returning after treatment and a lower chance of dying from cancer.
Oral chemotherapy extends survival in biliary tract cancer. A clinical trial with 447 people diagnosed with biliary tract cancer showed that taking capecitabine (Xeloda) after surgery lengthened their lives by more than a year compared to people who did not take capecitabine. Capecitabine is a type of chemotherapy taken by mouth.
See more: http://view.broadcastemail.asco.org/?qs=92dab06da42e760ac10ebf8c51e215040f81a9eebac3161a385db364a14bbd1eaab40eddebd629bad9595bdc60450633235b4f3fdff8ee2ea7fbd25fca504eec5d0a10772193bfe24f1994b4fe0850e0